On December 27th, China Economic Net reported that the US stock market of Genxi Biotechnology (NASDAQ: GRCL) closed at $9.92 on Tuesday, up 60.26%, with a total market value of $952 million.
According to the Daily Economic News, on December 26th, AstraZeneca announced that it had signed a final agreement on the acquisition proposal of Genxi Biotechnology Group (referred to as Genxi Biotechnology), further deepening AstraZeneca's layout in the field of cell therapy. Genxi Biotechnology is a global, clinical biopharmaceutical enterprise dedicated to developing innovative cell therapies for the treatment of tumors and autoimmune diseases. This proposed acquisition will add GC012F CAR-T cell therapy to AstraZeneca's expanding cell therapy pipeline. AstraZeneca stated that the total value of this transaction is approximately $1.2 billion, and Genxi Biotechnology will continue to operate as a wholly-owned subsidiary of AstraZeneca in China and the United States.